CymaBay Therapeutics Total Assets 2011-2026 | CBAY

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets CymaBay Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
435 M	142 M	202 M	154 M	206 M	187 M	104 M	19.4 M	43.1 M	37.5 M	32.5 M	8.12 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
435 M	8.12 M	131 M

Quarterly Total Assets CymaBay Therapeutics

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
451 M	227 M	245 M	142 M	159 M	178 M	201 M	202 M	123 M	117 M	137 M	154 M	154 M	154 M	154 M	206 M	206 M	206 M	206 M	187 M	187 M	187 M	187 M	104 M	104 M	104 M	104 M	19.4 M	19.4 M	19.4 M	19.4 M	43.1 M	43.1 M	43.1 M	43.1 M	37.5 M	37.5 M	37.5 M	37.5 M	32.5 M	32.5 M	32.5 M	32.5 M	8.12 M	8.12 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
451 M	8.12 M	118 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	94.6 M	$ 4.5	0.45 %	$ 862 M	Canada
ADC Therapeutics SA ADCT	529 M	$ 3.83	1.32 %	$ 105 M	Schweiz
Agenus AGEN	227 M	$ 3.64	9.31 %	$ 108 M	USA
Agios Pharmaceuticals AGIO	1.3 B	$ 35.08	-0.36 %	$ 2.03 B	USA
Akebia Therapeutics AKBA	377 M	$ 1.39	0.36 %	$ 357 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 3.95	-11.63 %	$ 266 B	Britain
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Aldeyra Therapeutics ALDX	72.1 M	$ 1.57	-5.42 %	$ 94.3 M	USA
Aligos Therapeutics ALGS	88.5 M	$ 8.08	1.38 %	$ 79.9 M	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Alnylam Pharmaceuticals ALNY	4.97 B	$ 331.14	3.85 %	$ 43.4 B	USA
Altimmune ALT	280 M	$ 3.4	1.8 %	$ 300 M	USA
ALX Oncology Holdings ALXO	59 M	$ 1.99	0.81 %	$ 107 M	USA
Amgen AMGN	90.6 B	$ 344.03	-1.12 %	$ 185 B	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Amneal Pharmaceuticals AMRX	3.68 B	$ 12.27	-1.68 %	$ 3.85 B	USA
Anika Therapeutics ANIK	271 M	$ 14.99	1.28 %	$ 220 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
ANI Pharmaceuticals ANIP	1.28 B	$ 73.8	-0.55 %	$ 1.43 B	USA
Annexon ANNX	278 M	$ 5.56	1.0 %	$ 862 M	USA
Annovis Bio ANVS	21.1 M	$ 2.56	12.28 %	$ 52.6 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aptorum Group Limited APM	16.1 M	$ 0.88	-5.16 %	$ 4.8 M	China
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Aprea Therapeutics APRE	15.9 M	$ 0.7	-1.87 %	$ 4.58 M	USA
Aquestive Therapeutics AQST	160 M	$ 4.12	-0.24 %	$ 441 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Arcturus Therapeutics Holdings ARCT	271 M	$ 8.14	1.31 %	$ 223 M	Israel
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Ardelyx ARDX	502 M	$ 5.99	0.84 %	$ 1.44 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
argenx SE ARGX	8.68 B	$ 749.99	0.48 %	$ 25 B	Niderland
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Arcutis Biotherapeutics ARQT	433 M	$ 24.06	1.82 %	$ 3.06 B	USA
Arvinas ARVN	718 M	$ 10.87	0.14 %	$ 771 M	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 60.28	-1.23 %	$ 8.06 B	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Assembly Biosciences ASMB	258 M	$ 29.51	1.72 %	$ 331 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.62	1.82 %	$ 8.71 B	Australia